Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
GI Dynamics, Inc.
About
  2. Companies
  3. GI Dynamics, Inc.
  4. News
10 News & Press Releases found

GI Dynamics, Inc. news

GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association

Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology

BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry and data from use within the Nat

Jul. 14, 2022

GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.

Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints

Findings Presented at DDW 2022

BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a multicenter s

Jun. 15, 2022

GI Dynamics Announces Approval of the I-STEP Clinical Study in India

BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE
developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to
announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India.

I-STEP is a multi-center, randomized, pivotal study evaluating the safety and efficacy of EndoBarrier® for glycemic
improvement in patients with inade

Jan. 30, 2022

GI Dynamics Appoints New Chief Executive Officer and Board of Directors

BOSTON — November 5, 2020 — GI Dynamics® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors (“the Board”) and Ginger Glaser as non-executive director to the

Nov. 5, 2020

GI Dynamics Completes Initial Closing of a $10 Million Series A Preferred Stock Financing from Crystal Amber

BOSTON — September 10, 2020 — GI Dynamics® Inc. (‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), the Company’s majority stockholder.

Sep. 9, 2020